Quest Diagnostics Incorporated (DGX)
Automate Your Wheel Strategy on DGX
With Tiblio's Option Bot, you can configure your own wheel strategy including DGX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DGX
- Rev/Share 96.875
- Book/Share 65.8571
- PB 2.7511
- Debt/Equity 0.8793
- CurrentRatio 1.1279
- ROIC 0.0803
- MktCap 19922732772.0
- FreeCF/Share 12.4375
- PFCF 14.302
- PE 20.6062
- Debt/Assets 0.394
- DivYield 0.0177
- ROE 0.1375
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | DGX | Robert W. Baird | Outperform | Neutral | -- | $194 | Aug. 25, 2025 |
| Initiation | DGX | Redburn Atlantic | -- | Buy | -- | $195 | April 2, 2025 |
| Downgrade | DGX | Citigroup | Buy | Neutral | -- | $185 | March 4, 2025 |
| Upgrade | DGX | Leerink Partners | Market Perform | Outperform | $169 | $174 | Jan. 6, 2025 |
| Upgrade | DGX | Morgan Stanley | Equal Weight | Overweight | $145 | $172 | Dec. 17, 2024 |
| Resumed | DGX | Jefferies | -- | Buy | $175 | $185 | Dec. 10, 2024 |
| Upgrade | DGX | Robert W. Baird | Neutral | Outperform | $157 | $182 | Oct. 23, 2024 |
| Resumed | DGX | Evercore ISI | -- | In-line | -- | $165 | Aug. 28, 2024 |
News
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Quest Diagnostics: Strong Q3, Steady (Not Spectacular) Growth Ahead
Published: October 22, 2025 by: Seeking Alpha
Sentiment: Positive
Quest Diagnostics Incorporated announced its Q3 earnings yesterday - revenues year-to-date are $8.23bn, and net income $845m. DGX is finally demonstrating a strong post-pandemic recovery, with Q3 revenues up 13% and ambitious growth initiatives in advanced diagnostics and strategic partnerships. DGX's diverse client base, operational improvements, and recent acquisitions position it for steady, double-digit top and bottom-line growth over the next several years.
Read More
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Quest Diagnostics (DGX) Surpasses Q3 Earnings and Revenue Estimates
Published: October 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Quest Diagnostics (DGX) came out with quarterly earnings of $2.6 per share, beating the Zacks Consensus Estimate of $2.51 per share. This compares to earnings of $2.3 per share a year ago.
Read More
Quest Diagnostics raises annual profit and revenue forecasts on lab test demand
Published: October 21, 2025 by: Reuters
Sentiment: Positive
Laboratory operator Quest Diagnostics raised its full-year forecast for profit and revenue on Tuesday, banking on robust demand for its diagnostic tests.
Read More
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
Third quarter revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024 Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.58 and $8.66; and adjusted diluted EPS is expected to be between $9.76 and $9.84 SECAUCUS, N.J. , Oct. 21, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter …
Read More
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
DGX is poised for solid Q3 2025 results, backed by strong DIS growth, strategic M&A and robust test demand across key health segments.
Read More
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.
Read More
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
Read More
Quest Diagnostics Incorporated (DGX) Presents at Jefferies 2025 Healthcare Services Conference Transcript
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Quest Diagnostics Incorporated (NYSE:DGX ) Jefferies 2025 Healthcare Services Conference September 29, 2025 4:35 PM EDT Company Participants Sam Samad - Executive VP & CFO Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay, we're going to kick it off. I'm Tycho Peterson from the life science team at Jefferies.
Read More
4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.
Read More
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
DGX posts strong gains from physician and hospital channels while advancing AI-powered solutions.
Read More
Quest Diagnostics Incorporated (DGX) Presents At Baird Global Healthcare Conference 2025 Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Quest Diagnostics Incorporated (NYSE:DGX ) Baird Global Healthcare Conference 2025 September 10, 2025 10:50 AM EDT Company Participants James Davis - Chairman, CEO & President Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Presentation Eric Coldwell Senior Research Analyst Thanks, everyone, for joining us.
Read More
Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering
Published: September 04, 2025 by: PRNewsWire
Sentiment: Neutral
New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J. , Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced pharmacogenomic (PGx) laboratory test service designed to help providers understand the patient's individual genetic response to select drug therapies.
Read More
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Quest Diagnostics (DGX) is a Top-Ranked Momentum Stock: Should You Buy?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
DGX Stock Gains Following a New Joint Venture With Corewell Health
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Quest Diagnostics shares rise after forming a joint venture with Corewell Health to expand advanced lab services across Michigan.
Read More
Why Is Quest Diagnostics (DGX) Up 8.2% Since Last Earnings Report?
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
Read More
Should Quest Diagnostics Stock Be in Your Portfolio Right Now?
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Negative
DGX drives growth with advanced diagnostics, acquisitions and cost savings, but rising debt and macro risks weigh on its outlook.
Read More
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference
Published: August 15, 2025 by: PRNewsWire
Sentiment: Neutral
SECAUCUS, N.J. , Aug. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2025 Global Healthcare Conference in New York City on Wednesday, September 10, 2025, at 10:50 a.m.
Read More
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Quest Diagnostics Incorporated (DGX) Q2 2025 Earnings Call Transcript
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2025 Earnings Conference Call July 22, 2025 8:30 AM ET Company Participants James E. Davis - Chairman, CEO & President Sam A.
Read More
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.
Read More
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.
Read More
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
About Quest Diagnostics Incorporated (DGX)
- IPO Date 1996-12-17
- Website https://www.questdiagnostics.com
- Industry Medical - Diagnostics & Research
- CEO James E. Davis
- Employees 55000